FRESENIUS SE+CO.KGAA O.N./ DE0005785604 /
| 12/6/2023 5:56:49 PM | Chg. +0.3300 | Volume | Bid6:50:30 PM | Ask6:50:30 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 28.6000EUR | +1.17% | 9,062 Turnover: 257,047.1300 |
28.6200Bid Size: 441 | 28.7500Ask Size: 439 | 16.11 bill.EUR | 3.22% | 11.72 |
GlobeNewswire
6/11/2021
UPDATE -- Humacyte Expands Strategic Global Partnership with Fresenius Medical Care
GlobeNewswire
11/11/2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medica...
GlobeNewswire
11/4/2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medica...
GlobeNewswire
10/29/2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Fresenius Medica...
GlobeNewswire
10/23/2019
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fresenius Medic...
GlobeNewswire
6/9/2017
KISSEI TO MARKET AVACOPAN IN JAPAN FOR VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA
GlobeNewswire
1/27/2011
Swedish Orphan Biovitrum agrees with Fresenius Biotech to distribute Removab®